STOCK TITAN
  1. Home
  2. Sec-filings
  3. RPTX
  4. [8-K] Repare Therapeutics Inc. Reports Material Event

[8-K] Repare Therapeutics Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock RPTX logo
Repare Therapeutics Inc.

NASDAQ:RPTX

RPTX Rankings

#5019 Ranked by Market Cap
N/A Ranked by Dividends

RPTX Latest News

Aug 8, 2025
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Jul 15, 2025
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
May 13, 2025
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
May 1, 2025
Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates
May 1, 2025
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

RPTX Latest SEC Filings

Aug 8, 2025
[10-Q] Repare Therapeutics Inc. Quarterly Earnings Report
Aug 8, 2025
[8-K] Repare Therapeutics Inc. Reports Material Event
Jun 20, 2025
[8-K] Repare Therapeutics Inc. Reports Material Event

RPTX Stock Data

72.60M
38.99M
1.25%
64.94%
1.6%
Biotechnology
Pharmaceutical Preparations
Link
Canada
SAINT-LAURENT